N-Terminal Fragment of Brain-Type Natriuretic Peptide (NT-proBNP) as a Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma Complicated by Dialysis-Dependent Renal Failure

Семочкин, С. В.; Misyurina, E.; Zhelnova, E.; Yurova, E.; Gagloeva, D.; Арефьева, Н. А.; Ушакова, А. И.; Kotenko, O.N. Kotenko; Tolstykh, Tatiana; Sinyavkin, D.O.; Baryakh, E. A.; Yatskov, K V; Самсонова, И. В.; Лысенко, М. А.

doi:10.1007/s10517-019-04506-z

Cited by 2 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It suggested that elevated levels of NT-proBNP were associated with disease severity of MM patients. BNP and NT-proBNP were associated with heart function, Semochkin SV et al [25] prospectively analyzed 20 patients with newly diagnosed MM and patients with high levels of NT-proBNP had shorter OS. This study also found that BNP or NT-proBNP > 2 ULN was an independent risk factor for UHR MM.…”

Section: Discussionmentioning

confidence: 99%

Characteristics and Risk Factors of Ultra-High-Risk Patients with Newly Diagnosed Multiple Myeloma

Geng

Yang

Zhou

et al. 2023

JPM

View full text Add to dashboard Cite

Objective: To investigate the clinical characteristics and risk factors of ultra-high-risk (UHR) patients with newly diagnosed multiple myeloma (MM). Methods: We screened UHR patients with a survival of less than 24 months and we selected patients with a concurrent survival of more than 24 months as a control group. We retrospectively analyzed the clinical characteristics of UHR patients with newly diagnosed MM and screened related risk factors. Results: In total we analyzed 477 patients, which included 121 (25.4%) UHR patients and 356 (74.6%) control patients. Median overall survival (OS) and progression-free survival (PFS) of UHR patients was 10.5 months (7.5–13.5 months) and 6.3 months (5.4–7.2 months), respectively. Univariate logistic regression analysis showed that age > 65 years, hemoglobin (HGB) < 100 g/L, lactate dehydrogenase (LDH) > 250 U/L, serum creatinine (SCr) > 2 mg/dL, corrected serum calcium (CsCa) > 2.75 mmol/L, B-type natriuretic peptide (BNP) or N-terminal prohormone BNP (NT-proBNP) > 2 upper limit of normal (ULN), high-risk cytogenetics, Barthel index score, and International Staging System (ISS) stage III were associated with UHR MM. In a multivariate analysis, age > 65 years, LDH > 250 U/L, CsCa > 2.75 mmol/L, BNP or NT-proBNP > 2 ULN, high-risk cytogenetics, and Barthel index score were independent risk factors for UHR MM. Moreover, UHR patients had a worse response rate than control patients. Conclusion: Our study highlighted the characteristics of UHR MM patients and suggested that the combination of organ insufficiency and highly malignant myeloma cells resulted in poor outcomes of patients with UHR MM.

show abstract

Section: Discussionmentioning

confidence: 99%